Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement Regarding Non-Preemptive Redemption of "Note Convertible Bonds"
Nanjing Securities Co., Ltd.'s verification opinion on Jiangsu Notai Ausino Biopharmaceutical Co., Ltd.'s non-early redemption of "Notai Convertible Bonds".
Jiangsu Sinopep-Allsino Biopharmaceutical: Meeting material for the first bondholder meeting of the "Notai Convertible Bonds" in 2024.
Jiangsu Sinopep-Allsino Biopharmaceutical: Materials for the first ad-hoc shareholders' meeting in 2024.
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement on the Expected Redemption Conditions of "Notai Convertible Bonds".
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement regarding the change in the proportion of convertible bond holdings by bondholders reaching 10%.
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement of convertible bonds conversion results and share changes.
CSI Enterprise Bond Index issued convertible bonds to unspecified parties, and entrusted management affairs report (2023).
Jiangsu Sinopep-Allsino Biopharmaceutical: Notice of the First Extraordinary Shareholders' Meeting in 2024
Jiangsu Notai Ausen Bio-Pharmaceutical Co., Ltd. issues convertible enterprise bonds for the second time to unspecified entities. Interim trustee management report.
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement regarding changes to some of the fundraising projects.
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement regarding the use of a portion of the raised funds to increase capital for a wholly-owned subsidiary to implement the fundraising project.
Jiangsu Sinopep-Allsino Biopharmaceutical: Notice Regarding the Holding of the First Bonds Holders Meeting of Nortel Convertible Bonds in 2024.
Jiangsu Sinopep-Allsino Biopharmaceutical: Risk warning notice about the suitability requirements for convertible bond investors.
Jiangsu Sinopep-Allsino Biopharmaceutical: Risk warning notice about the suitability requirements for convertible bond investors.
Jiangsu Sinopep-Allsino Biopharmaceutical: Risk warning notice about the suitability requirements for convertible bond investors.
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement on the conversion of "Notai convertible bonds" into shares.
Jiangsu Sinopep-Allsino Biopharmaceutical: Risk warning notice about the suitability requirements for convertible bond investors.
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement regarding the debt-for-equity swaps conversion price adjustment for the 2023 annual equity distribution of convertible bonds.
Jiangsu Notai Ausen BioPharma Co., Ltd. issued the first interim trustee management report (2024) for convertible corporate bonds to unspecified parties.
No Data